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Abstract
A screen for hepatitis C virus (HCV) NS3 helicase inhibitors revealed that the commercial dye
thioflavine S was the most potent inhibitor of NS3-catalyzed DNA and RNA unwinding in the
827-compound National Cancer Institute Mechanistic Set. Thioflavine S and the related dye
primuline were separated here into their pure components, all of which were oligomers of
substituted benzothiazoles. The most potent compound (P4), a benzothiazole tetramer, inhibited
unwinding >50% at 2±1 μM, inhibited the subgenomic HCV replicon at 10 μM, and was not toxic
at 100 μM. Because P4 also interacted with DNA, more specific analogs were synthesized from
the abundant dimeric component of primuline. Some of the 29 analogs prepared retained ability to
inhibit HCV helicase but did not appear to interact with DNA. The most potent of these specific
helicase inhibitors (compound 17) was active against the replicon and inhibited the helicase more
than 50% at 2.6±1 μM.
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INTRODUCTION
The hepatitis C virus (HCV) infects about 170 million people worldwide causing profound
morbidity and mortality.1 HCV is typically treated with various combinations of the
nucleoside analog ribavirin combined with recombinant human alpha interferon. Though
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such treatments are effective, therapy is poorly tolerated, expensive, and not equally
effective against all HCV genotypes.2 Better HCV treatments are therefore being modeled
on other antivirals, which unlike interferon and ribavirin directly attack proteins that HCV
synthesizes in human cells. Such “direct acting antivirals” (DAAs) typically are small
molecules that inhibit viral enzymes, with the most common targets being the HCV RNA
polymerase and an HCV protease. Two HCV protease inhibitors, telaprevir3 and
boceprevir,4 were recently approved for use in HCV patients, but neither alone eradicates
HCV infection because HCV rapidly evolves to become resistant to these first generation
DAAs.5 Protease inhibitors need to be administered with interferon and ribavirin, and
consequently, many patients still poorly tolerate the new therapies. The overall goal of this
project is to find new DAAs for HCV that might be used with telaprevir, boceprevir or
similar drugs to replace interferon and ribavirin in HCV therapy.
Telaprevir and boceprevir both inhibit the HCV nonstructural protein 3 (NS3). NS3 is one of
ten proteins derived from the ca. 3,000 amino acid-long polypeptide encoded by the HCV
RNA genome. Viral and host proteases cleave the HCV polyprotein into mature structural
(core, E1, E2) and non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B).
The HCV nonstructural proteins form four enzymes. NS5B is a polymerase that synthesizes
new viral RNA. The NS2 and NS3 proteins combine to form an autocatalytic protease. NS3
and NS4A combine to form a serine protease that cuts itself, cleaves the NS4B/NS5A,
NS5A/NS5B junctions, and some cellular proteins. Most relevant to the present work, NS3
is also an ATP-fueled helicase that can separate and re-arrange RNA/RNA, RNA/DNA and
DNA/DNA nucleic acid duplexes and displace nucleic acid bound proteins.6
Helicases have been widely studied as potential drug targets although progress has been
slower than other viral enzymes.7, 8 Nevertheless, HCV needs a functional helicase to
replicate in cells,9–11 and small molecules that inhibit HCV helicase-catalyzed reactions also
inhibit cellular HCV RNA replication.12–14 In this paper, we report a new class of
compounds that inhibit the NS3 helicase and also act against the HCV replicon. We describe
the procurement of these inhibitors via isolation from commercial samples of thioflavine S
and primuline, two chemically related dye preparations, and through the chemical synthesis
of congeners based on those isolated leads.
RESULTS
Assay Development and Screening
Numerous HCV helicase inhibitors have been reported in the literature, but many of these
also bind the helicase nucleic acid substrate. HCV inhibitors that interact with DNA or RNA
could also inhibit cellular nucleic acid enzymes like RNA polymerase,15 therefore such
compounds might not act like true DAAs. The goal of this study was to identify chemical
probes that specifically target NS3. Such compounds are needed to better understand why
the virus encodes a helicase, which may lead to better candidates for drug development. To
facilitate HCV helicase inhibitor identification, Belon & Frick developed a new helicase
assay that simultaneously identifies compounds that interact with the helicase substrate and
compounds that inhibit helicase action.16 This molecular beacon-based helicase assay
(MBHA) uses a dual-labeled hairpin-forming DNA oligonucleotide annealed to a longer
oligonucleotide, which forms a tail for the helicase to load (Figure 1A). Once ATP is added,
the helicase displaces the molecular beacon, resulting in a decrease in substrate
fluorescence. By comparing substrate fluorescence before ATP is added (F0), one can
identify compounds that bind the MBHA substrate. At the same time, compounds that
inhibit helicase action can be identified by fluorescence changes in an MBHA before and 30
minutes after ATP addition (F30/F0 ratio). In other words, the MBHA can be used as an
“internal” counter-screen to identify compounds that appear to affect unwinding because
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they interfere with the assay. The most common types of interfering compounds are those
that fluoresce or absorb light at the same wavelengths as the MBHA Cy5-labeled substrate.
Alternatively, other compounds may bind the DNA substrate and distort it to change how
the quenching moiety on the beacon is oriented relative to the Cy5 fluorophore.
To identify HCV helicase inhibitors, the MBHA was used to screen the National Cancer
Institute Developmental Therapeutics Program's Mechanistic Set Library (http://
dtp.nci.nih.gov/branches/dscb/mechanistic_explanation.html). In total, 827 compounds (at
20 μM) were screened using a MBHA with a DNA substrate (Table S2, Supporting
Information). When compound interference was plotted versus percent inhibition (Figure
1B), it was clear that the majority of compounds that appeared to inhibit HCV helicase also
quenched fluorescence of the MBHA substrate. Compound interference in the MBHA was
evaluated by comparing the fluorescence of assays containing each compound to the
fluorescence of DMSO-only negative controls before the addition of ATP. Hits were defined
as those compounds that did not interfere with the assays more than 20%, of which twelve
were identified. These twelve hits were then subjected to a counterscreen that was designed
to independently identify compounds that exhibit DNA-binding properties using a modified
fluorescent intercalator displacement (FID) assay.17 The FID counterscreen used ethidium
bromide to determine a molecule's ability to bind DNA, and is based on the assumption that
a DNA-binding compound displaces a fluorescent DNA intercalating agent, leading to a
decrease in observed fluorescence. Compounds were tested at 1.5 μM in the presence of the
25 base-pair substrate used in the helicase assays (Figure 1C). Results showed that even at a
compound concentration 13-times lower than that used in the MBHA, most of the hit
compounds decreased the fluorescence of an ethidium bromide-DNA complex by more than
10%, indicative of the molecule's ability to bind DNA. The DNA minor-groove-binding
compound Berenil (IC50=1.6±0.1 μM) was used a positive control in all FID assays.18
Four compounds decreased the fluorescence of DNA-bound ethidium bromide less than 8%.
The first, CdCl2, was a known HCV helicase inhibitor that binds in place of the magnesium
ion needed for ATP hydrolysis to fuel unwinding.19 The second, ellipticine, was found to
fully quench DNA-bound ethidium bromide fluorescence at higher concentrations, and the
IC50 value for ellipticine in MBHAs (5.6±0.8 μM) was similar to its apparent affinity for
DNA, suggesting that it inhibited the helicase by interacting with the substrate.
Chromomycin A3 inhibited HCV helicase-catalyzed-DNA unwinding with an IC50 of
0.15±0.03 μM, but had no effect on HCV helicase-catalyzed RNA unwinding (data not
shown). This false positive can be explained by the fact that Chromomycin A3, functionally
resembles ethidium bromide and they both represent fluorescent DNA-binding
compounds.20 This result also demonstrates that not all DNA binding compounds will
decrease DNA-bound ethidium bromide fluorescence in an ethidium bromide-based FID
assay. The final sample, thioflavine S, did not affect DNA-bound ethidium bromide
fluorescence until its concentration exceeded 100 μM, at which point a 20% fluorescence
decrease was observed. In concentration response experiments (Figure 1D), thioflavine S
inhibited HCV helicase-catalyzed DNA-unwinding with an IC50 of 10±1 μM, and it
inhibited HCV catalyzed RNA unwinding with an IC50 of 12±2 μM. The related dye
thioflavine T, which, like thioflavine S, is used to specifically stain Alzheimer amyloid
plaques21 and had no effect on either HCV-catalyzed DNA- or RNA-unwinding (data not
shown).
Purification & Characterization of HCV Helicase Inhibitors
Thioflavine S is not a single compound but rather a heterogeneous dye that is structurally
related to another heterogeneous yellow dye, primuline.22 Primuline (MP Biomedicals cat.
#195454) inhibited HCV helicase in MBHAs with about twice the potency as thioflavine S
(Table 1). To better understand how these dyes inhibit HCV helicase, both dye mixtures
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were separated using reverse-phase preparative HPLC or a combination of normal-phase
silica gel column chromatography and reverse-phase preparative HPLC.
The structure of commercial samples of thioflavine S is not reported consistently or is left
intentionally vague, creating confusion over the chemical identity of the screening hit. For
instance the MSDS (Sigma Aldrich) for thioflavine S describes the compound only as
“methylated, sulfonated primuline base.” In the NCI and PubChem online databases,
thioflavine S (NSC71948, SID550242) was reported as a mixture of methylated
benzothiazoles, and Packham's group reported the same structure.23 To identify the
components of commercially obtained thioflavine S responsible for the observed activity,
we purified the commercial sample (Sigma cat. #T1892) via reverse-phase preparative
HPLC to obtain two compounds (T1 and T2), the structures of which were assigned using
NMR, and LC/MS (Figure 2).
Contrary to our expectation that the isolated compounds would be methylated primuline
derivatives, isolated T1 and T2 were the N, N-diethyl products of the primuline monomeric
and dimeric benzothiazoles. Both T1 and T2 manifested some inhibitory activity against
helicase-catalyzed DNA unwinding (Figure S1, supplemental information, Table 1), but
neither was as potent as thioflavine S or primuline, suggesting that a minor component of
the dye was inhibiting HCV helicase action.
In total, six compounds were purified from primuline. The two major components, P1a and
P2a, were separated via reverse-phase preparative HPLC in 9.2% and 7.6% isolated yield
(by weight for P1a and P2a, respectively). In the MBHA, P2a was significantly less potent
than the primuline mixture, while P1a was effectively inactive. That the purified major
active component, P2a, did not possess increased potency compared to the mixture
containing the inactive P1a was unexpected and hinted that, perhaps, highly potent
components could be present in the primuline mixture in small amounts. The direct isolation
of minor components via reverse-phase preparative HPLC of the dye mixture was not
successful. Hence, the purification procedure was modified, enabling the isolation of four
minor components. Four chromatographic bands enriched with minor components (UV and
LC-MS) were obtained from silica gel chromatography of commercial primuline upon
elution with 20% DCM/MeOH. Subsequent reverse-phase preparative HPLC purification
afforded the relatively minor components P1b, P2b, P3 and P4, where P3 and P4
represented 0.49% and 0.23% isolated yield (by weight) of the dye, respectively. All
purified compounds were composed of a central benzothiazole oligomer of 1–4 units
terminating with a p-aminobenzene group (Figure 2).
In the MBHA, all of the compounds purified from primuline were helicase inhibitors
although P1a and P1b, only partially inhibited unwinding at the highest concentrations
tested (Figures S1, Supporting Information). Potency correlated with the length of the
benzothiazole chain. For P3 or P4, only about 1 μM of either was needed to reduce the rate
of helicase-catalyzed DNA-unwinding by 50% (Figure 3B, Table 1).
These purified compounds resemble molecules known to bind DNA, typically along the
minor groove, such as the cyanine dye known as BEBO,24, 25 but unlike many DNA-binding
benzothiazoles, these helicase inhibitors are not positively charged. Instead they are anionic,
due to the sulfonate group on the terminal benzothiazole rings. FID assays with the purified
compounds revealed that they, indeed, possessed some ability to bind DNA. Like thioflavine
S, all compounds, except T1, P1a and P1b, decreased the fluorescence of ethidium bromide-
bound DNA by at least 10% when present at 100 μM. However, only compounds P3 and P4
decreased ethidium bromide-bound DNA fluorescence more than 50% at the highest
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concentration tested (100 μM). P3 decreased the fluorescence of ethidium bromide-bound
DNA with an EC50 of 55±20 μM, and P4 decreased fluorescence with an EC50 of 15±3 μM.
Because P3 and P4 clearly interacted with ethidium bromide-stained DNA, we suspected
that the other benzothiazoles might also bind DNA, but in ways that do not displace the
intercalated ethidium bromide. We therefore examined the effect of each compound on
DNA stained with other dyes, and found that most compounds decreased the fluorescence of
DNA stained with SYBR Green I. The affinity of primuline, thioflavine S and the purified
compounds for the MBHA substrate DNA was therefore estimated using a modified FID
assay where ethidium bromide was replaced with SYBR Green I. The results were less
drastic compared to those seen with ethidium bromide, with P4 binding slightly more tightly
than all other compounds (Table 1).
It should be noted that, assuming that IC50 values in the MBHA reflect dissociation
constants for a compound-helicase-DNA complex, and EC50 values reflect the affinity of a
compound for DNA it appears thioflavine S and primuline bind the helicase complex more
tightly than they bind DNA, and that P4 binds DNA 17-times more weakly. These data
suggest that little, if any, compound was bound to DNA in MBHAs at concentrations needed
to inhibit helicase action, suggesting that the yellow dye-derived benzothiazoles inhibit
HCV helicase directly.
If the purified benzothiazoles inhibit helicase-catalyzed nucleic acid unwinding by directly
binding NS3, then they might also inhibit other functions of NS3, namely ATP hydrolysis in
the presence and absence of stimulating nucleic acids. The most potent compound, P4 was
therefore added to NS3 ATPase assays. The compound inhibited both assays in a dose-
dependent manner (Figure 3C). P4 inhibited ATP hydrolysis both in the presence and
absence of RNA, indicating that the compound is not simply sequestering RNA and
preventing activation of ATP hydrolysis. It is also interesting to note that far more P4 is
needed to inhibit ATP hydrolysis in the absence of RNA, indicating that the presence of
nucleic acid might enhance the enzyme's affinity for inhibitors (Figure 3A). It is not
uncommon for helicase inhibitors to inhibit the protein's ability to hydrolyze ATP, since
ATP hydrolysis is needed to fuel unwinding. When ATPase assays were performed with
compounds isolated from thioflavine S and primuline (Table 1) the same pattern was
observed as previously seen in the MBHAs and FIDs (i.e. the longer benzothiazole
oligomers were always more potent in all assays than the shorter oligomers).
Most of the compounds isolated from the two yellow dyes are fluorescent, absorbing light
around 340 nm, and emitting near 420 nm. Their extinction coefficients and peak absorption
wavelengths increase as the length of the benzothiazole oligomer increases. Their relative
fluorescence decreases with the length of the benzothiazole chain. None of the compounds
absorbed light near the excitation or emission wavelengths of the Cy5-labeled MBHA
substrate, or the wavelengths where ethidium bromide-stained DNA, SYBR Green I-stained
DNA, NS3-catalyzed peptide cleavage, or ATP hydrolysis were measured.
To test if the above compounds might be useful as HCV antiviral agents, they were added to
cells harboring a HCV subgenomic RNA replicon. The HCV replicon chosen was derived
from the same HCV strain (genotype 1b) as the NS3 protein used for screening and enzyme
assays, and was a variant of the replicon first reported by Lohmann et al.26 with two cell
culture adaptive mutations (E1202G and S2204I).27, 28 The subgenomic replicon used here
also had a Renilla luciferase gene fused to the 5'-end of the neomycin phosphotransferase
gene used for selection, so that the cellular levels of Renilla luciferase correlated directly
with the amount of HCV RNA present in cells.29 After replicon transfection and selection,
cells were treated in parallel with one of the compounds purified from thioflavine S and
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primuline, or one of four recently reported HCV helicase inhibitors 1–4,14, 30–32 in two
triplicate sets (Figure 4, and Table 2). One set of cells was used for renilla luciferase assays
and the other set was used to determine cell viability using a firefly luciferase-based assay
and all compounds were tested at 10 μM. While none of the compounds isolated from the
yellow dyes were notably toxic to cells, only P3 and P4 showed any ability to decrease the
amount of HCV RNA present in the cultures. The ability of P3 and P4 to inhibit HCV
replication was similar to that of the comparison helicase inhibitors tested. None of the
comparison helicase inhibitors were particularly toxic at 10 μM except for 1. Only
compound 3 inhibited MBHAs with a potency similar to the yellow dyes, although the
precise effects of compounds 3 and 4 on HCV helicase action were difficult to assess
because both interfered with the MBHA (Figure S2, Supporting Information).
Synthesis of primuline analogs
The positive results obtained with some of the higher-order components of thioflavine S and
primuline led us to undertake a structure-activity relationship study based on them.
However, difficulties with both isolation of sufficient quantities from the commercial
sources and with fully synthetic approaches necessitated that we consider more accessible
bioisosteric equivalents. Accordingly, we focused on modification of the amino group at the
terminus of P2a, which was isolable from commercial primuline in sufficient quantities to
serve as a starting material. We envisioned that an appropriately rigid linker could substitute
for the third benzothiazole ring of P3. Thus, the terminal amine of P2a was acylated to give
amides, and reacted with isocyanates or sulfonyl chlorides to give urea analogs and
sulfonamides, respectively (Scheme 1). Table 3 and Figure S3 (Supporting Information)
illustrate the effect of various functional groups on substituted phenyl amide derivatives.
These included electron-donating or -withdrawing groups as well as aliphatic moieties.
While replacing the para substitution R=H with NH2, OCH3, CO2CH3, t-Bu and N(CH3)2
had no significant effect on the potency of helicase inhibition, replacement with F, Br and
NHFmoc groups led to slightly more potent analogs (2-fold, compared to R=H). Even better
analogs (3–5-fold) were obtained when Cl, CH3, CF3 and 2-naphthalene (33, Table 4,
replacement of phenyl group of 5) groups were used. The increased size of alkyl substitution
from Me to t-Bu resulted in an ca. 3-fold activity loss. Altering the Cl position from para to
meta had no effect on helicase inhibition, although the compound with meta substitution
displayed weaker DNA binding. Increasing the number of chloro groups as in 18 showed no
improvement. Moving the CF3 group from the para position to the ortho or meta position
resulted in a loss of inhibitory activity (7–10 fold, compounds 12, 19 and 20). Introduction
of additional fluorines to the derivatives also exhibited no effect on the helicase inhibition
when compared to 12 (see 21 to 27). In fact, depending on the position of fluorine
substitution, a significant decrease in potency was observed. In DNA-binding assays, none
of the P2a derivatives decreased the fluorescence of DNA-bound ethidium bromide by more
than 10%, even at 100 μM. Like P3 and P4, many of the derivatives appeared to bind SYBR
Green I-stained DNA. However unlike P3 and P4, many of the derivatives did not displace
more than 50% SYBR Green at the highest concentration tested (100 μM). Therefore, to
compare the DNA-binding potential of all derivatives, the percent SYBER Green displaced
at the highest concentration tested (100 μM) was compared rather than an EC50 values
(Tables 3 and 4). Most of the amide derivatives were at least a 10-fold more potent in the
MBHA than the DNA-binding assay.
Two additional classes of chemical linkers were also explored to mimic the benzothiazole
moiety (Table 4). The urea analogs, which were synthesized from P2a by reacting P2a with
different isocyanates and the sulfonamide analogs prepared via the sulfonation of P2a with
sulfonyl chlorides. The urea analog 28 has comparable potency in the MBHA to the amide
analog 11, although increased DNA binding was observed (13 μM for 28 compared to >100
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μM for 11). Less potent analogs were achieved via sulfonation (e.g. 29, 2-fold activity drop)
compared to 11. Replacing substituted phenyl with methyl resulted in complete loss of
activity (30). Analogs targeting improved solubility by replacing the phenyl ring of with
pyridine ring, produced less potent analogs (2–5 fold decrease in helicase activity, 31, 32).
N-methylation of the naphthyl analog 33 also caused a significant drop in activity (5-fold,
34), which could indicate the loss of a key hydrogen bond interaction.
In an effort to mimic the tetrameric structure of P4, the more elaborate amide derivatives 35
and 36 were synthesized. No improvements in potency were observed for the tetrameric
analogues 35 and 36 over the previous trimeric analogs. The simple one-step synthesis of the
trimeric analogs compared to the tetrameric analogs prompted us to focus on the former for
future studies targeting more potent inhibitors of helicase function and HCV replication.
When all derivatives (5 to 36) were compared with the purified compounds and the recently
reported helicase inhibitors (1 to 4), it is clear that most compounds that bound DNA in the
FID assay also interfered with the MBHA by quenching substrate fluorescence (Figure 5A).
The most potent benzothiazoles were notably more effective than the recently reported
helicase inhibitors used for comparison, two of which appeared to function primarily by
interacting with the DNA substrate (compounds 3 and 4). Compound 17 (Figure 5A) was the
most potent compound that did not interfere with the MBHA, and it eliminated the HCV
replicon without apparent toxicity, similar to both P3 and P4. Also like P4, compound 17
inhibited HCV helicase-catalyzed RNA-unwinding and ATP hydrolysis (data not shown).
The pharmacokinetic (PK) properties of compound 17 were profiled using a standard panel
of assays (Table 5). The most striking result is the solubility variation depending on the
buffer system used. While the aqueous solubility is low in the PBS--based solvent system, in
both the detergent-containing (Tween 20) assay matrix and the proprietary Prisma HT buffer
system the compound is readily soluble. The unknown identity of the components in the
Prisma HT buffer system complicates further speculation into the solubility discrepancy.
The solubility results have inspired us to pursue improving compound solubility through
formulation with other solubilizing agents and these experiments are currently in progress.
The low solubility and permeability of compound 17 were not surprising for a polycyclic
aromatic compound of molecular weight 592 g/mol. Encouragingly, compound 17 was
highly stable under the various conditions screened and possessed no detectable hepatic
toxicity. Analogs possessing improved solubility and PAMPA properties will be the aim of
future efforts.
DISCUSSION
One of the challenges in developing chemical probes that target helicases is that potent
helicase inhibitors often exert their actions by binding nucleic acid helicase substrates. Such
compounds lack specificity because they can inhibit any protein that needs to access the
genetic material. We attempted to discover more specific helicase inhibitors that do not
target nucleic acids using high throughput helicase and DNA-binding assays. However, even
the most promising compounds, which were purified from the most active compound-library
sample, interacted with the DNA substrate in the absence of protein. We have, nevertheless,
been able to engineer potent analogs that interact with DNA less tightly, yet still retain an
ability to inhibit helicase-catalyzed nucleic acid-strand rearrangements. Some of these
compounds retain the important ability to inhibit HCV replication in cells, and could
therefore prove useful for antiviral drug development.
To discover helicase inhibitors that do not bind nucleic acids, we screened a compound
library using a helicase assay that simultaneously detects a compound's ability to interact
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with the helicase substrate and its ability to interfere with the movement of HCV helicase
through DNA. The results of the screen confirmed that most compound-library samples that
block helicase movements also interact with the helicase substrate. Using a DNA binding
assay, we confirmed that most of the newly uncovered HCV helicase inhibitors interact with
DNA (Figure 1C). The binding assay was based on a FID assay17 that monitors fluorescence
changes that occur when a compound interacts with DNA stained with ethidium bromide.
The most active sample in the screened compound-library that least affected the
fluorescence of ethidium bromide-stained DNA was a yellow dye called thioflavine S, and
potent benzothiazole oligomers were purified from this dye and its relative, primuline. When
the most active benzothiazole oligomers purified from primuline were found to interact with
SYBR Green-stained DNA, we learned that the ethidium bromide-based FID failed to detect
the interaction of thioflavine S with DNA. A more sensitive SYBR Green assay was
therefore developed and used to chemically optimize more specific P2a derivatives. The
observation that DNA-interactions escaped detection in the ethidium bromide-based FID
reinforces the notion that care needs to be taken when using FID assays, since DNA-binding
compounds might not displace the bound intercalator. There is likewise still some
uncertainty as to whether or not the P2a derivatives that failed to influence the fluorescence
of SYBR Green-stained DNA interact with nucleic acids. Preliminary results using
isothermal titration calorimetry support the relative affinities reported here, but more
extensive DNA-and RNA-binding experiments clearly need to be done with these
compounds.
The compounds reported here are more potent and specific than other recently reported
HCV helicase inhibitors (Table 2, Figure 5). However, we have not been able to reproduce
all of the results previously reported for the comparison helicase inhibitors. For example, the
nucleotide mimic (compound 1), which had been reported to have a Ki of 20 nM,30 had
almost no detectable effect on the MBHA at 5,000 times higher concentration (Table 2 &
Fig. S2). Compound 1 had some antiviral activity and it was coupled with notable toxicity at
10 μM (Figure 4). The acridone (compound 2) was about 17-fold less potent in our helicase
assay than it was in a previously reported assay, yet it still was one of the most effective
compounds in eliminating the HCV replicon. Similarly, although its interaction with the
helicase substrate obscured effects in our MBHA, the triphenylmethane (compound 3)
displayed no inhibition at its previously reported IC50 of 12 μM, and the compound did not
appear as cytotoxic as had been reported.32 Compound 4 had antiviral activity as previously
reported, but again, compound interference in the MBHA made its effect on the helicase in
vitro difficult to judge.31 Our different results could be due to several factors, including the
use of different recombinant HCV helicase proteins and assay conditions (Figure S2).
In conclusion, we have found that the commercial dyes thioflavine S and primuline contain
potent compounds for the inhibition of the NS3 helicase of HCV. We show here that minor
components of primuline inhibit both the HCV helicase and HCV replicon replication. The
antiviral potential of these trimeric and tetrameric benzothiazoles inspired the derivatization
of the more abundant dimeric constituent. Several derivatives were found to be close in
potency to the isolated trimer or tetramer in the MBHA and to possess improved DNA
binding profiles. Importantly, the antiviral potential of this class of helicase inhibitors does
not appear to depend entirely on either their ability to inhibit HCV helicase or bind DNA.
We speculate that the ability to inhibit HCV replication results from a compound's ability to
enter Huh7.5 cells, which can be monitored by examining compound fluorescence when
they are administered to cells. In cultures, both primuline and thioflavine S mainly stain
membranes, but preliminary data suggest that some of the derivatives might enter cells.
Effects of the most potent replicon inhibitors on HCV replication (e.g. 11, 17, 24 and 26) are
presently being examined in more detail. The results of these studies will be used to inform
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Thioflavine S and primuline were purchased from Sigma (Cat. #T1892, Lot #048K1656)
and MP Biomedicals (Cat #195454, Lot #7792J), respectively. The Mechanistic Diversity
Library was obtained from the National Cancer Institute (NCI, http://dtp.cancer.gov/
repositories.html). All other reagents were purchased from commercial suppliers and used as
received. Methylene chloride, acetonitrile, toluene, ethyl ether and THF were dried by being
passed through two packed columns of anhydrous, neutral alumina prior to use. HPLC/MS
analysis was carried out with gradient elution (5% CH3CN to 100% CH3CN) on an Agilent
1200 RRLC with a photodiode array UV detector and an Agilent 6224 TOF mass
spectrometer. Compound purity was determined using RP HPLC and was measured on the
basis of peak integration (area under the curve) from UV/vis absorbance (at 214 nm), and
compound identity was determined on the basis of exact mass analysis. All compounds used
for biological studies have purity >95% (Table S1, Supporting Information) except for the
following compounsds: P3 (89.2%), P4 batch 2 (85.6%), 6 (90.0%), 11 (89.1%), 14
(80.4%), 17 (93.6%), 28 (93.2%), 32 (94.4%) and 36 (88.6%).
All oligonucleotides were purchased from Integrated DNA Technologies (IDT, Coralville,
IA). The partially duplex DNA substrates used in MBHAs consisted of a helicase substrate
forming 25 base pairs and consists of a 45-mer bottom strand 5'-GCT CCC CGT TCA TCG
ATT GGG GAG C(T)20- 3' and the 25-mer HCV top strand 5'-Cy5-GCT CCC CAA TCG
ATG AAC GGG GAG C-IBRQ-3'. The 19-base pair RNA substrate used in MBHAs
consisted of a 39 nucleotide long bottom strand 5'-AGU GCC UUG ACG AUA CAG
C(U)20-3' and the 24 nucleotide long top strand 5'-Tye665-AGU GCG CUG UAU CGU
CAA GGC ACU-IBRQSp-3'. Underlined areas denote hairpin-forming regions. DNA and
RNA substrates were annealed and purified as described previously.16
The cloning, expression, and purification of His-tagged recombinant HCV NS3 protein have
been described previously.33–36
Helicase Assays
All Molecular Beacon-based Helicase Assays (MBHAs) were performed as described
before.16, 36 For screening the NCI library, MBHAs contained 25 mM MOPS pH 6.5, 1.25
mM MgCl2, 5.0 nM MBHA substrate, 12.5 nM NS3h_1b(con1), 5 μg/ml BSA, 0.01% (v/v)
Tween20, 0.05 mM DTT with 20 μM each test compound (2% v/v final DMSO). In each
flat, black 384-well plate, 56 compounds were tested, in triplicate, along with 3 negative
controls (DMSO only), 3 positive controls (500 nM dT20), and 2 wells with no enzyme.
Fluorescence was read before ATP (F0) addition and 30 minutes after ATP was added to 1
mM (F30) using a Tecan Infinite M200 fluorescence microplate reader with excitation and
emission wavelengths set to 643 and 670 nm, respectively. Percent inhibition was calculated
with equation 1, and compound interference in the MBHA was calculated with equation 2.
(Equation 1)
Li et al. Page 9














In equations 1 & 2, Fc0 is the fluorescence of the reactions containing the test compound
before adding ATP, Fc30 is the fluorescence of the test compound reaction 30 minutes after
adding ATP. F(−)0 is the average of 3 DMSO-only negative control reactions before adding
ATP and F(−)30 is the average of three DMSO-only reactions 30 minutes after adding ATP.
To monitor helicase reaction kinetics and to calculate IC50 values, MBHAs were performed
in 60 μL in white ½ area 96-well plates and measured in a Thermo Varioscan Multimode
reader (Thermo Scientific) using the 643 nm excitation wavelength and 667 nm emission
wavelengths. Reactions were again performed by first incubating all components except for
ATP for two minutes, then initiated by injecting in 1/10 volume of ATP such that the final
concentration of all components was as noted above. Conditons were as described above
except that 5% v/v DMSO was present in each assay. Initial reaction velocities were
calculated by fitting first-order decay equation to data obtained after ATP addition and
calculating an initial velocity from the resulting amplitude and rate constant. The
concentration at which a compound causes a 50% reduction in reaction velocity (IC50) was
calculated by fitting compound concentration to initial velocity using equation 3:
(Equation 3)
where, v0 is the velocity observed in DMSO-only controls-inhibition, h is the Hillslope
coefficient, and [I] is the concentration of test compound.
DNA Binding Assays
Fluorescent intercalation displacement (FID) assays18 were used to measure the ability of a
compound to bind the MBHA substrate. The concentration at which half the ethidium
bromide is displaced (EC50), was determined using the different conditions as above to more
closely mimic the conditions of a standard helicase assay. Each 100 μL reaction contained
25 mM MOPS pH 6.5, 0.16 μM MBHA DNA substrate (lacking Cy5 and IBQ-RQ
modifications), 2 μM ethidium bromide, and various concentrations of test compound.
Fluorescence of ethidium bromide was monitored using excitation and emission
wavelengths of 545 and 595 nm, respectively, on a Cary Eclipse fluorescence
spectrophotometer in white 96-well plates. The amount of ethidium bromide-DNA complex
fluorescence was used to estimate the ability of compound to bind DNA, and therefore
displace the fluorescent intercalator (ethidium bromide).
(Equation 4)
In equation 4, Fc is the fluorescence in the presence of the compound, F(−) is the average
DMSO-only negative controls, and F(+) is the average positive controls (100 μM berenil).
EC50 values were from a normalized concentration-response curve.
A modified FID assay in which ethidium bromide was replaced with SYBR Green I
(Invitrogen) was used to estimate a compound's affinity for the MBHA substrate. Reactions
were performed as described above except that the DNA substrate was present at 0.32 μM,
ethidium bromide was absent and SYBR Green was present at (0.68 μM). Data were
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normalized as described above and fit to concentration-response equation using GraphPad
Prism software. Titrations with each compound were performed in triplicate and EC50
values from three independent titrations are reported ± standard deviations. Average percent
bound at 100 μM is reported for compounds that did not decrease the fluorescence of SYBR
Green stained DNA more than 50% at the highest concentration tested.
ATP Hydrolysis Assays
A modified “malachite green” assay was used to measure ATP hydrolysis.37 50 μL
reactions contained 25 mM MOPS pH 6.5, 5 mM MgCl2, 2 mM ATP, 5 μg/ml BSA, 0.01%
(v/v) Tween20, 0.05 mM DTT, and poly(U) RNA (Saint Louis, MO) as indicated. Reactions
were initiated by adding NS3h_1b(con1). Reactions were incubated for 15 minutes at 37 °C
then stopped by mixing 40 μL of the reaction into 200 μL of the malachite green reagent (3
volumes 0.045% (w/v) malachite green: 1 volume 4.2% ammonium molybdate in 4N HCl:
0.05 volume of 20% Tween 20). 25 μL of 34% sodium citrate was quickly added to each
reaction and color allowed to develop for 15 minutes. Absorbance at 630 nm was
proportional to the concentration of phosphate produced; free phosphate produced was
measured against a standard curve.
HCV Subgenomic Replicon Assay
An HCV Renilla luciferase (HCV RLuc) reporter construct was used to measure the effect
of each compound on cellular HCV RNA levels. The replicon was a generous gift from
Seng-Lai Tan. In HCV RLuc, the HCV internal ribosome entry site (IRES) drives the
translation of the neomycin and Renilla luciferase genes while the HCV nonstructural
proteins (NS3 to NS5B) are translated from the Encephalomyocarditis virus IRES.29 The
plasmid DNA was cleaved with Sca I, purified by phenol/chloroform extraction followed by
ethanol precipitation, and used as template for RNA transcription using MEGAscript™ T7
RNA transcription kit (Ambion, Austin, TX). The RNA transcripts were treated with 2 U
DNase I (Ambion) at 37 °C for 30 min, purified by acid phenol/chloroform extraction,
followed by isopropanol precipitation, and suspended in diethylpyrocarbonate-treated water.
RNA concentration was determined by spectrophotometry by measuring the OD260. RNA
integrity and size was checked on 1% agarose gel. Transcribed RNA was stored in aliquots
at −80 °C until needed.
Huh-7.5 cells RNA were transfected with HCV RNA by electroporation. Briefly,
subconfluent Huh7.5 cells were trypsinized, suspended in complete growth medium, and
centrifuged at 1,000 × g for 5 min at 4 °C. The cell pellets were then washed twice with ice-
cold phosphate-buffered saline (PBS) and suspended at 1.75 × 107 cells/mL in ice-cold PBS.
Replicon RNA (5 μg) was mixed with 0.4 mL of cell suspension and transferred to 2 mm
gap width electroporation cuvette (Eppendorf AG, Germany) and pulsed with 5 times for 99
μsec at 820 V over 1.1 sec intervals using the ECM 830 electroporator instrument (BTX
Havard Apparatus, Holliston, MA). After 5 min recovery period at room temperature, cells
transferred to 10 ml complete growth medium, and seeded into 10 cm diameter cell culture
dishes. Twenty-four hours after transfection, the medium was replaced with fresh complete
DMEM supplemented with 1 mg/ml geneticin (Invitrogen) and the medium was replaced
every three to four days with fresh medium containing 1 mg/mL geneticin. Geneticin-
resistant colonies were selected for a period of two weeks and expanded in the presence of
250 μg/mL geneticin.
HCV RLuc replicon cells were seeded at a density of 10 × 103 cells per well in 96-well
plates and incubated for 4–5 h to allow the cells to attach to the plate. The compounds
dissolved in dimethyl sulfoxide (DMSO) were added at a final concentration of 10 μM
(DMSO solvent final concentration was 0.5%) and the cells were incubated for 72 h at 37 °C
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under 5% CO2 atmosphere. The effects of compounds on HCV replication were then
assessed by measuring the Renilla luciferase activity in compound-treated versus DMSO-
treated cells. At the end of the incubation period, the medium was aspirated and the cells
were washed with 1 × PBS. The Renilla luciferase reporter gene assay was performed using
the Renilla luciferase assay kit (Promega, Madison, WI) according to the manufacturer's
instructions. Briefly, the cells were lysed by addition of 50 μL of 1× Renilla luciferase lysis
buffer followed by two cycles of freeze/thaw. The luciferase activity content of the lysate
was measured with a FLUOstar Omega microplate reader instrument (BMG Labtech,
Germany) after injecting 50 μL of luciferase substrate and reading for 5 s.
Cell Viability Assay
To assess compound toxicity towards Huh-7.5 cells, cells were plated and treated as above
and cell viability was assessed using the CellTiter-Glo luminescent cell viability kit
(Promega) following the manufacturer's instructions. Briefly, at the end of a 72 h incubation
period, the medium was aspirated and the cells were washed with 1× PBS, then an equal
volume of growth medium and CellTiter-Glo reagent was added and the lysis was initiated
by mixing on an orbital shaker. The plate was incubated at 23 °C for 30 min and the
luciferase activity was measured for 1 s using the FLUOstar Omega microplate reader
(BMG Labtech).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Discovery of thioflavine S as a HCV helicase inhibitor. (A) Schematic drawing of the
MBHA mechanism. (B) The NCI Mechanistic Set of 827 compounds was screened with an
MBHA, each at 20 μM. Fluorescence was read before and 30 minutes after ATP addition
and compound inhibition was calculated from F30/F0 ratios. Hits were defined as
compounds inhibiting more than 50% and interfering less than 20%. (C) Hits from the
MBHA primary screen were tested for their DNA-binding capacity with an FID
counterscreen at 1.5 μM compound concentration, and percent binding was calculated.
Numbers refer to NSC numbers. (D) Concentration response curves for thioflavine S when
assayed in MBHAs using either a DNA or RNA substrate.
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Structures of isolated, pure compounds from thioflavine S (T) and primuline (P) dyes.
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Effects of primuline and its components on HCV helicase-catalyzed DNA-unwinding and
ATP hydrolysis. (A) MBHAs performed at various concentrations of primuline. Reactions
were initiated by adding ATP at the indicated time. (B) Initial rates of DNA unwinding in
MBHAs containing indicated concentrations of primuline (*), compound P1a (circles), P3
(triangles), or P4 (diamonds). Data are fit to Equation 3 (methods). Individual reaction time-
courses and curve-fits used to calculate initial rates are shown in Figure S1 (supplemental
data). IC50's listed in Table 1 are the averages from three separate titrations with each
compound. (C) ATPase assays were performed in the absence of RNA (squares), 15 μM
(circles) or 1 mM (triangles) poly(U) RNA (measured as μM UMP). ATP was present at 1
mM, the reactions were initiated by rapidly mixing in NS3h, and the amount of phosphate
released was measured after 15 minutes at 26 °C. Various concentrations of P4 were present
as indicated.
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Effect of various compounds on Huh7.5 hepatoma cells harboring a stably transfected
subgenomic rLuc HCV replicon. All compounds were tested at 10 μM such that cell media
contained 0.5% (v/v) DMSO. Percent renilla luciferase, which is proportional to HCV RNA
content is expressed with regard to cells grown in media and 0.5% DMSO. Cell viability
was measured with the Titer-Glo luminescent cell viability kit (Promega) and is also
expressed compared to DMSO controls.
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Comparative effects of benzothiazoles in HCV helicase assays. (A) Potency of each
compound in MBHAs is plotted against the interference observed in an MBHA performed in
the presence of 10 μM of each compound. Points are labeled with compound number,
although some numbers are omitted for clarity. Compounds that bind the helicase DNA
substrate and quench its fluorescence lie on the left side of the plot while those that enhance
substrate fluorescence are on the right. (B) Effects of various concentrations of the most
potent compound that does not interfere with the MBHA (compound 17) in standard
MBHAs where Cy5 fluorescence was monitored.
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a Reagents: (a) Substituted benzoyl chloride, pyridine, 80 °; (b) arylisocyanate, DMF, 80 °;
(c) arylsulfonyl chloride, pyridine, 80 °.
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Table 1




DNA Binding (ethidium bromide)
a
EC50 (μM)






Thioflavine S 24±1.3 >100 61±37 50±17
T1 33±24 >100 ND >100
T2 26±21
b >100 ND ND
Primuline 12±1 >100 43±14 67±27
P1a 70±31 >100 >100 >100
P1b 122±5 >100 >100 >100
P2a 49±45
b >100 ND ND
P2b 10±4.6 73±36 32±3 >100
P3 0.9±0.1 55±20 ND 15±4
P4 0.9±0.4
c 15±3 15±8 5±3
a
Helicase (MBHA), DNA binding (FID), and ATP hydrolysis were monitored in the presence of 8 different concentrations of each compound (2-
fold dilution series starting at 100 μM). IC50 values were determined from concentration-response curves. All values are means ± standard
deviations from three independents titrations with inhibitor. ND, not determined.
b
Average value from three different batches of compound.
c
Average value from two different batches of compound.
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Table 2




DNA Binding (ethidiuM bromide)
a
EC50 (μM)






1 >100 >100 >100 >100
2 25±6 >100 >100 >100
3 17±7 4±2 20±2 >100
4 19±8 >100 74±21 >100
a
Helicase (MBHA), DNA binding (FID), and ATP hydrolysis were monitored in the presence of 8 different concentrations of each compound (2-
fold dilution series starting at 100 μM). IC50 values were determined from concentration-response curves. All values are means ± standard
deviations from three independents titrations with inhibitor. ND, not determined.
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